Treatment & Research Archives

February 3, 2025

Next Therapies After Noncovalent BTK Inhibitors

As more and more drugs have become available to treat CLL, doctors and patients alike want to know what is the best way to sequence these therapies.

February 2, 2025

BTK Degraders and T Cell Function

BTK degrader NX-2127 enhanced T cell function in the lab, suggesting that it may mitigate CLL-associated immunosuppression.

January 28, 2025

Sonrotoclax and Zanubrutinib as a Frontline CLL Treatment

The combination of sonrotoclax and zanubrutinib was well-tolerated and produced high rates of undetectable disease in patients with treatment-naïve CLL.

January 28, 2025

Undetectable Measurable Residual Disease in CLL / SLL

Undetectable measurable (minimal) residual disease (uMRD) has strong prognostic significance in CLL and may, in the future, guide the duration of therapy.

January 24, 2025

What’s New in CLL Therapies at ASH 2024

Dr. Nicole Lamanna discusses upcoming novel therapies for CLL / SLL from the American Society for Hematology (ASH) annual meeting, a scientific conference.

January 10, 2025

AMPLIFY Trial: Acalabrutinib Plus Venetoclax for CLL

The AMPLIFY trial of acalabrutinib plus venetoclax, with or without obinutuzumab, could lead to the FDA approval of the first all-oral frontline CLL therapy.

December 17, 2024

New Options for Treatment-Resistant CLL

New novel agents are being tested in clinical trials to help patients with CLL who have developed resistance to all the BTK inhibitors and BCL2 inhibitors.

December 2, 2024

Progression-Free and Overall Survival Correlation in Relapsed CLL

There is a strong correlation between progression-free survival (PFS) and overall survival (OS) in relapsed / refractory (R/R) CLL / SLL.

December 2, 2024

Acalabrutinib and Obinutuzumab for Frontline CLL Treatment

Acalabrutinib plus obinutuzumab had a 100 percent response rate at 14 months and a deep reduction of disease in the bone marrow in treatment-naive CLL.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Treatment & Research

Next Therapies After Noncovalent BTK Inhibitors

BTK Degraders and T Cell Function

Sonrotoclax and Zanubrutinib as a Frontline CLL Treatment

Undetectable Measurable Residual Disease in CLL / SLL

What’s New in CLL Therapies at ASH 2024

AMPLIFY Trial: Acalabrutinib Plus Venetoclax for CLL

New Options for Treatment-Resistant CLL

Progression-Free and Overall Survival Correlation in Relapsed CLL

Acalabrutinib and Obinutuzumab for Frontline CLL Treatment

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT